Latecomer PD-1/L1 drug Jemperli has achieved impressive Phase III results in first line endometrial cancer, and GSK hopes it can “redefine” care, especially in dMMR patients. Rival Merck, however, has other ideas.

The US firm’s lead program has flunked a mid-stage trial in early Parkinson’s disease and, despite a promising efficacy signal in a younger patient cohort, its future remains uncertain.

In this special podcast from Medtech Insight, editor Reed Miller talked to Andrie Leday, the US vice president for ambulatory surgery centers (ASCs) at Johnson & Johnson/DePuy Synthes. Leday's group is dedicated to creating a new "ecosystem" around DePuy Synthes broad range of orthopedic implants and tools to meet the demand of an aging population.

The German major has pinned its early-stage research colors to the masts of oncology, cardiovascular, neurology, rare diseases and immunology, representing a shift away from rather than an abandonment of women’s health.